YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Elicio Therapeutics Inc. BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cance…
(RTTNews) - Elicio Therapeutics, Inc. (ELTX), a clinical-stage biotechnology company, announced that it has entered into a definitive securities purchase agreement with two institutional investors and participation by a large existing shar…
* Elicio Therapeutics (ELTX [https://seekingalpha.com/symbol/ELTX]) priced [https://seekingalpha.com/pr/20571020-elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering] a $15M registered direct offering led by two n…
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that…
(RTTNews) - Today's leading biotech gainers include Can-Fite, following an update from its pancreatic cancer study; SeaStar Medical, driven by improving quarter-over-quarter revenue for its flagship product; and Elicio, which has refined i…
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at newa…
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at newa…
(RTTNews) - Today's top gainers included uniQure, which rallied after the FDA softened its stance on the company's investigational gene therapy; Elicio Therapeutics, following encouraging treatment responses from its cancer vaccine in panc…
Dividends binder by Elena_Dig via Shutterstock The news of a deal between the U.S. and Iran to reopen the Strait of Hormuz sent markets higher yesterday. The S&P 500 and Nasdaq Composite gained 1.65% and 3.07%, respectively. While the mood…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.65%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.92%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.06%. June E-mini S&P futures (ESM26) rose +1.68%, and June E-mi…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.65%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.92%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.06%. June E-mini S&P futures (ESM26) rose +1.68%, and June E-mi…
Elicio Therapeutics (ELTX) said Monday its Phase 2 clinical study evaluating the experimental pancre PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) today is up +1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.73%. June E-mini S&P futures (ESM26) are up +1.61%, and June E-mini Nasdaq futu…
The S&P 500 Index ($SPX) (SPY) today is up +1.67%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.24%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.79%. June E-mini S&P futures (ESM26) are up +1.72%, and June E-mini Nasdaq futu…
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that it…
The S&P 500 Index ($SPX) (SPY) today is up +1.67%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.24%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.79%. June E-mini S&P futures (ESM26) are up +1.72%, and June E-mini Nasdaq futu…
The S&P 500 Index ($SPX) (SPY) today is up +1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.73%. June E-mini S&P futures (ESM26) are up +1.61%, and June E-mini Nasdaq futu…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Price swings ahead of the opening bell are being driven by clinical trial and regulatory updates, as well as trial endpoint misses. In the Green - Premar…
* Elicio Therapeutics press release [https://seekingalpha.com/pr/20435956-elicio-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates] (ELTX [https://seekingalpha.com/symbol/ELTX]): FY GAAP EPS of -$2.58. *…
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announc…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Quest Diagnostics (DGX) been one of those stocks this year? A quick glance at the company's year-to…
The total pancreatic cancer market size is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research and the development of better diagnostic tools, which may improve the disease prognosis. Additionall…
Elicio Therapeutics Inc. Strategic Hire Strengthens Late Phase and Commercial Readiness as Elicio Advances Lymph Node-Targeted Immunotherapy Pipeline BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elici…
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announc…
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomiz…
DelveInsight Business Research LLP The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Merc…
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant setting Trial is anticipated to begin enrolling in H1’2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics…
BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announ…
(RTTNews) - Elicio Therapeutics (ELTX), Wednesday announced new data from its Phase 2 AMPLIFY-7P trial, showing that 99 percent of evaluable patients treated with its investigational cancer vaccine, ELI-002 7P, generated strong mKRAS-speci…
At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) induced by ELI-00277% re…
Key Points Elicio Therapeutics (NASDAQ:ELTX) reported a net loss per share of $0.66 (GAAP) for the second quarter, beating the analyst estimate of $(0.69) (GAAP). Research and development (R&D) expenses (GAAP) decreased 14.6% year-over-yea…
Syringe and red cross by Stadratte via iStock Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people wil…
BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announc…
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clin…
BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, toda…
We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Elicio Therapeutics Inc (NASDAQ:ELTX) stands against the other healthcare stocks. The h…